For many private biotech companies, a successful initial public offering (IPO) remains a major aspiration as it can be a crucial catalyst for growth. It’s a move that can deliver vital funding for ...

Biotech funding has been in a down cycle for roughly the past four years. Higher interest rates, tighter capital markets, and ...